Seizert Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Seizert Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-48,182	Closed	-$7.95M	–	194
2020 Q4	$7.95M	Sell	48,182 -4,747	-9%	-$707K	0.46%	57
2020 Q3	$7.55M	Sell	52,929 -12,719	-19%	-$1.58M	0.5%	52
2020 Q2	$7.24M	Sell	65,648 -8,701	-12%	-$962K	0.49%	49
2020 Q1	$7.42M	Sell	74,349 -11,164	-13%	-$1.44M	0.55%	50
2019 Q4	$12.8M	Sell	85,513 -14,186	-14%	-$1.93M	0.64%	48
2019 Q3	$12.8M	Sell	99,699 -1,546	-2%	-$207K	0.64%	52
2019 Q2	$14.4M	Buy	+101,245	New	+$13.6M	0.71%	51

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Seizert Capital Partners's JAZZ Position: Q1 2021 in Review

Seizert Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 48,182 shares — an estimated $7.95M sold.

Seizert Capital Partners first reported a position in JAZZ in Q2 2019 and held it in 7 quarters. The position peaked at $14.4M in Q2 2019. 442 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

Seizert Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Seizert Capital Partners sold 48,182 Jazz Pharmaceuticals shares in Q1 2021, an estimated $7.95M.
Seizert Capital Partners first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 7 quarters.
Seizert Capital Partners's Jazz Pharmaceuticals position peaked at $14.4M in Q2 2019.
442 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Seizert Capital Partners's 13F filing for Q1 2021, filed 5 May 2021.